ArticleDermatology and therapy2022

Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 Trial.

Diamant Thaçi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.